TuHURA Biosciences Earnings Call Transcripts

Fiscal Year 2026

Canaccord Genuity's 46th Annual Growth Conference

The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.

Read full transcript →